days, there were no death, follow-up myocardial infarction or stent thrombosis. There was however 1 case of target vessel revascularization not related to BVS. Conclusions: These preliminary results suggest that complex lesions can possibly be successfully treated with BVS. Intravascular ultrasound guidance and meticulous technique may be important to optimize clinical outcomes.
Background: Percutaneous transluminal septal ablation (PTSMA) is an alternative treatment to surgery in patients with hypertrophic obstructive cardiomyopathy (HOCM) with advanced symptoms despite optimal medical treatment, specially under high surgical risk. However, due to the relatively new introduction of the technique the very long term results of PTSMA (>10 years) are unknown. Methods: We have included in the present study consecutive patients with HOCM treated with PTSMA in 5 centers between 1998 and 2003. We have analyzed clinical, hemodymanic and echocardiographic data at baseline and follow up. Results: A total of 45 patients were included, 31 (69%) women and mean age 62.4AE 14 years. Among those 39 (86.6%) were in NYHA class III or IV. The septum thickness was 21.8AE3.5 mm, maximum basal gradient in echo 77AE39 mmHg and mitral regurgitation was at least moderate in 22 (48.8%). In hospitalization 3 pts required permanent pacemaker implantation and 1 pt had ventricular perforation (by pacing lead) undergoing surgery. After a median follow up of 12.3 years (11-13.5), 9 pts died and among these 2 pts (4.4%) suffered cardiac death (heart failure and post-transplantation), 2 pts underwent ICD implantation (the case with perforation and surgery due to subsequent ventricular tachycardia, and other for primary prevention), 2 underwent cardiac surgery (endocarditis and severe mitral regurgitation). In the last clinical review NYHA class was I-II in 39 (86.6%), (p<0.0001), the maximum basal gradient was 16AE23 mmHg (p<0.0001) and mitral regurgitation was absent or mild in 34 (75.5%) (p < 0.03).
Conclusions:
The results of this study suggest safety and efficacy for PTSMA at a very long term follow up, over 10 years. A sustained reduction in gradients, mitral regurgitation and functional class is observed. This treatment was not associated with significant incidence of sudden death or ventricular arrhythmias.
TCT-435
Early experience of CT angiography in planning alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM) Background: ASA is an established treatment for HOCM. Up to 30% have an unsatisfactory outcome from intended treatment. Methods: CT images are used to highlight the SAM-septal contact point. Vascular supply to this area is identified, the course and origin of these vessels are described. The target septal is labeled and a 3D angiogram created to define optimal angiographic angles. All major epicardial arteries are surveyed to identify any further target vessels and exclude those with an inappropriate distribution. Results: 16 patients have undergone CT angiography prior to ASA. The approach to ASA was changed in 9. CT can identify septal arteries that bifurcate to supply both the left and right ventricular septum. Contrast injection into the ostium of such arteries localises to the RV due to the pressure differential between coronary flow to RV and LV. On balloon occlusion of the LV sub-branch the contrast localises to the target area. CT can reliably determine the sub-branch that supplies the target area. This has occurred in 6/16 patients. 3 patients had epicardial artery source other than LAD (circumflex, diagonal, obtuse marginal). 12 patients have received alcohol and have >1 month review. 11/12 have improved dyspnoea (one has progressive pulmonary fibrosis). LVOT gradients have decreased by >50% from baseline to a final level of <50mmHg in all. Peak VO2 is improved in all 6 who have undergone 6-month testing. Conclusions: CT has the ability to describe intricate details of septal arterial anatomy. Our approach to ASA is changing and contrast localisation is more accurate. Initial results are very encouraging. TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
